OSU-2S is a potent PKCδ activator; it inhibits cell proliferation and migration, induces apoptosis, and exhibits anticancer activity; when used in combination with Sorafenib, it reduces p-ERK1/2 expression and increases PKCδ (38 kDa) expression; it is also a non-immunosuppressive analog of FTY720.